Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models

Cancer Research

Volumn 76, Issue 8, 2016, Pages 2432-2442

  Dermawan, Josephine Kam Tai ^a,b   Hitomi, Masahiro ^a,b   Silver, Daniel J ^a   Wu, Qiulian ^a   Sandlesh, Poorva ^c   Sloan, Andrew E ^b   Purmal, Andrei A ^d   Gurova, Katerina V ^c   Rich, Jeremy N ^a,b   Lathia, Justin D ^a,b   Stark, George R ^a,b   Venere, Monica ^a,b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d CLEVELAND BIOLABS INC   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CBL 0137; CHAPERONE; FACILITATES CHROMATIN TRANSCRIPTION PROTEIN; LAPATINIB; OCTAMER TRANSCRIPTION FACTOR 4; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; CBLC137; DNA BINDING PROTEIN; HIGH MOBILITY GROUP PROTEIN; QUINAZOLINE DERIVATIVE; SSRP1 PROTEIN, HUMAN; TRANSCRIPTION ELONGATION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIMERIZATION; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS; MOUSE; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; BRAIN TUMOR; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; CARBAZOLES; DNA-BINDING PROTEINS; GLIOBLASTOMA; HIGH MOBILITY GROUP PROTEINS; HUMANS; MICE; QUINAZOLINES; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 84970951402     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2162     Document Type: Article

References (46)

1. Stupp R, Brada M, van den Bent M, Tonn J, Pentheroudakis G. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:93-101.
2. Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
3. Brennan C,Verhaak R,McKenna A,Campos B,Noushmehr H, SalamaS, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
4. Pelloski C, Ballman K, Furth A, Zhang L, Lin E, Sulman E, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25:2288-94.
5. Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: A systematic review. Curr Oncol Rep 2014;16:390.
6. Emlet D, Gupta P, Holgado-Madruga M, Del Vecchio C, Mitra S, Han S, et al. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res 2014;74:1238-49.
7. Mazzoleni S, Politi L, Pala M, Cominelli M, Franzin A, Sergi L, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010;70:7500-13.
8. Padfield E, Ellis H, Kurian K. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol 2015;5:5.
9. Peereboom D, Shepard D, Ahluwalia M, Brewer C, Agarwal N, Stevens G, et al. Phase II trial of erlotinibwith temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010;98: 93-9.
10. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2010;65:353-61.
11. Clark P, Iida M, Treisman D, Kalluri H, Ezhilan S, Zorniak M, et al. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 2012;14:420-8.
12. Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6.
13. Bao S,Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A, et al. Glioma stem cells promote radioresistance by preferential activation of theDNAdamage response. Nature 2006;444:756-60.
14. Lathia J, Mack S, Mulkearns-Hubert E, Valentim C, Rich J. Cancer stem cells in glioblastoma. Genes Dev 2015;29:1203-17.
15. Venere M, Fine H, Dirks P, Rich J. Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy. Glia 2011;59: 1148-54.
16. Venkatesh S, Workman J. Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol 2015;16:178-89.
17. Garcia H, Fleyshman D, Kolesnikova K, Safina A, Commane M, Paszkiewicz G, et al. Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells. Oncotarget 2011;2:783-96.
18. Garcia H, Miecznikowski J, Safina A, Commane M, Ruusulehto A, Kilpinen S, et al. Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers. Cell Rep 2013;4:159-73.
19. Gurova K, Hill J, Guo C, Prokvolit A, Burdelya L, Samoylova E, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kBdependent mechanism of p53 suppression in tumors. Proc Natl Acad SciU S A 2005;102:17448-53.
20. Gasparian A, Burkhart C, Purmal A, Brodsky L, Pal M, Saranadasa M, et al. Curaxins: Anticancer compounds that simultaneously suppress NF-kB and activate p53 by targeting FACT. Sci Transl Med 2011;3:1-12.
21. Dermawan J, Gurova K, Pink J, Dowlati A, De S, Narla G, et al. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-kB, and cell-cycle progression innon-small cell lung cancer.MolCancer Ther 2014;13:2203-14.
22. Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget 2014;30:11038-53.
23. Koman I, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, et al. Targeting FACT complex suppresses mammary tumorigenesis in HER2/neu transgenic mice. Cancer Prev Res 2012;5:1025-35.
24. Carter D, Murray J, Cheung B, Gamble L, Koach J, Tsang J, et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 2015;7:312ra176.
25. Eyler C,WuQ, Yan K,MacSwords J, Chandler-Militello D, Misuraca K, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011;146:53-66.
26. Schonberg D, Miller T, WuQ, Flavahan W, Das N, Hale J, et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 2015;28:441-55.
27. Chou T. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
28. Hu Y, Smyth G. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
29. Lathia J, Hitomi M, Gallagher J, Gadani S, Adkins J, Vasanji A, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2011;2:e200.
30. Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
31. Patel A, Tirosh I, Trombetta J, Shalek A, Gillespie S, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396-401.
32. Ben-Porath I, Thomson M, Carey V, Ge R, Bell G, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Gen 2008;40:499-507.
33. Wong D, Liu H, Ridky T, Cassarino D, Segal E, Chang H. Module map of stem cell genes guides creation of epithelial cancer stem cells.Cell StemCell 2008;2:333-44.
34. Bhattacharya B, Miura T, Brandenberger R, Mejido J, Luo Y, Yang A, et al. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood 2004;103:2956-64.
35. Müller F, Laurent L, Kostka D, Ulitsky I, Williams R, Lu C, et al. Regulatory networks define phenotypic classes of human stem cell lines. Nature 2008;455:401-5.
36. Barone TA, Burkhart CA, Safina A, Gurova KV, Haderski G, Purmal AA, et al. CBL0137 is efficacious in the treatment of preclinical orthotopic models of glioblastoma multiforme as monotherapy and in combination with temozolomide. Neuro-Oncology (submitted for publication).
37. Barone T, Burkhart C, Purmal A, Gudkov A, Gurova K, Plunkett R. ET- 006. Curaxin (CBL0137) significantly increases survival in orthotopic models of glioblastoma multiforme alone and in combination with temozolomide. Neuro Oncol 2013;15:iii37-iii61. Paper presented at the 4th Quadrennial Meeting of the World Federation of Neuro- Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA, 21 to 24 November 2013.
38. Shats I, Gatza M, Chang J, Mori S, Wang J, Rich J, et al. Using a stem cellbased signature to guide therapeutic selection in cancer. Cancer Res 2010;71:1772-80.
39. Morrison S, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006;441:1068-74.
40. Winkler D, Luger K. The histone chaperone FACT: Structural insights and mechanisms for nucleosome reorganization. J Biol Chem 2011;286: 18369-74.
41. Gill B, Pisapia D, Malone H, Goldstein H, Lei L, Sonabend A, et al. MRIlocalized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A 2014;26:12550-5.
42. Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, Buetow K. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 2009;7:157-67.
43. Venere M, Hamerlik P, Wu Q, Rasmussen R, Song L, Vasanji A, et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ 2013;21:258-69.
44. Boyer L, Lee T, Cole M, Johnstone S, Levine S, Zucker J, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-56.
45. Beier D, Schulz J, Beier C. Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol Cancer 2011;10:128.
46. Polivka J, Polivka J, Rohan V, Topolcan O, Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res 2012;32: 2935-46.